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Neuroticism is an important risk factor for psychiatric traits, 
including depression1, anxiety2,3, and schizophrenia4–6. At 
the time of analysis, previous genome-wide association 
studies7–12 (GWAS) reported 16 genomic loci associated to 
neuroticism10–12. Here we conducted a large GWAS meta-
analysis (n =  449,484) of neuroticism and identified 136 
independent genome-wide significant loci (124 new at the 
time of analysis), which implicate 599 genes. Functional fol-
low-up analyses showed enrichment in several brain regions 
and involvement of specific cell types, including dopami-
nergic neuroblasts (P =  3.49 ×  10−8), medium spiny neurons 
(P =  4.23 ×  10−8), and serotonergic neurons (P =  1.37 ×  10−7). 
Gene set analyses implicated three specific pathways: neu-
rogenesis (P =  4.43 ×  10−9), behavioral response to cocaine 
processes (P =  1.84 ×  10−7), and axon part (P =  5.26 ×  10−8). 
We show that neuroticism’s genetic signal partly originates 
in two genetically distinguishable subclusters13 (‘depressed 
affect’ and ‘worry’), suggesting distinct causal mechanisms 
for subtypes of individuals. Mendelian randomization analy-
sis showed unidirectional and bidirectional effects between 
neuroticism and multiple psychiatric traits. These results 
enhance neurobiological understanding of neuroticism and 
provide specific leads for functional follow-up experiments.
The meta-analysis of neuroticism comprised data from the 
UK Biobank study (UKB, full release14; n = 372,903; Methods 
and Supplementary Figs.  1 and 2), 23andMe, Inc.15 (n = 59,206), 
and the Genetics of Personality Consortium (GPC19; n = 17,375; 
Methods) (n = 449,484 in total). In all of the samples, neuroti-
cism was measured through (digital) questionnaires (Methods and 
Supplementary Note). To achieve optimal power, SNP associations 
were subjected to meta-analysis using METAL16, with weighting by 
sample size (Methods). We chose to perform meta-analysis on the 
available samples rather than use a two-stage discovery–replication 
strategy because Skol et al.17 showed that this is almost always 
more powerful, even though less correction for multiple testing is 
required in the replication stage.
The quantile–quantile plot of the genome-wide meta-analysis 
on 449,484 subjects and 14,978,477 SNPs showed inflation (link-
age disequilibrium score regression (LDSC)18: λGC = 1.65, mean χ 2 
statistic = 1.91; Fig. 1a and Supplementary Table 1), yet the LDSC 
intercept (1.02; standard error (s.e.) = 0.01) and ratio (2.1%) both 
indicated that the inflation was largely due to true polygenicity 
and the large sample size19. The λGC value of 1.65 is consistent with 
values observed in recent large-sample GWAS (n > 100,000) for 
diverse and polygenic traits (Supplementary Note). The LDSC SNP-
based heritability (hSNP
2 ) of neuroticism was 0.100 (s.e. = 0.003). 
The GWAS meta-analysis identified 9,745 genome-wide signifi-
cant SNPs (P < 5 × 10–8), of which 157 and 2,414 were located in 
known associated inversion regions on chromosomes 8 and 1710–12, 
respectively (Fig. 1b and Supplementary Fig. 3; see Supplementary 
Table 2 for cohort-specific information). We used FUMA20, a tool to 
functionally map and annotate results from GWAS (Methods), and 
extracted 170 independent lead SNPs (158 new; see the Methods for 
definition of lead SNPs) that mapped to 136 independent genomic 
loci (124 new at the time of analysis) (Methods, Supplementary 
Tables 3–8, and Supplementary Note). Of all the lead SNPs, 4 were 
in exonic regions, 88 were in intronic regions, and 52 were in inter-
genic regions. Of the 17,794 SNPs in high linkage disequilibrium 
(LD) with one of the independent significant SNPs (see the Methods 
for definition), most were intronic (9,147; 51.4%) or intergenic 
(5,460; 30.7%), and 3.8% were annotated as potentially having a 
functional impact, with 0.9% (155 SNPs) being exonic (Fig.  1c 
and Supplementary Table  9; see Supplementary Tables  10 and 11 
for an overview of the chromatin state and regulatory functions of 
these SNPs). Of these 155 SNPs, 70 were exonic nonsynonymous 
(ExNS) (Table 1 and Supplementary Table 12). The ExNS SNP with 
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the highest combined annotation-dependent depletion21 (CADD) 
score (which indicates the likelihood of the SNP being deleterious; 
Methods) was rs17651549 (CADD score of 34), located on chromo-
some 17 in exon 6 of MAPT, with a GWAS P value of 1.11 × 10−28, 
in high LD with the lead SNP in that region (r2 = 0.97). rs17651549 
is a missense mutation (c.1108 C > T:p.Arg370Trp) that leads to an 
arginine-to-tryptophan change with allele frequencies matching the 
inversion in that region. The ancestral C allele is associated with a 
lower neuroticism score (see Table 1 and Supplementary Table 12 
for a detailed overview of all functional variants in genomic risk 
loci).
Stratified LDSC22 (Methods) showed significant enrich-
ment for h2 of SNPs located in conserved regions (enrich-
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Fig. 1 | SNP-based associations with neuroticism in the GWAS meta-analysis. a, Quantile–quantile plot of the SNP-based associations with neuroticism 
(n =  449,484 individuals). SNP P values were computed in METAL using a two-sided, sample-size-weighted z-score method. b, Manhattan plot showing 
the –log10-transformed P value of each SNP on the y axis and base-pair positions along the chromosomes on the x axis (n =  449,484 individuals). SNP  
P values were computed in METAL using a two-sided, sample-size-weighted z-score method. The upper dashed line indicates genome-wide significance 
(P <  5 ×  10−8), and the lower dashed line shows the threshold for suggestive associations (P <  1 ×  10−5). c, Pie charts showing the distribution of functional 
consequences of SNPs in LD with genome-wide significant lead SNPs in the meta-analysis, the minimum chromatin state across 127 tissue and cell types, 
and the distribution of RegulomeDB score (a categorical score between 1a and 7, indicating biological evidence of a SNP being a regulatory element, with 
a low score denoting a higher likelihood of a SNP being regulatory). d, Heritability enrichment of 22 functional SNP annotations calculated with stratified 
LD Score regression (summary statistics of the meta-analysis of neuroticism were used as input for this analysis). The circles signify the estimated 
enrichment, whereas the dashed line indicates enrichment of 1. Error bars represent 95% confidence intervals. TSS, transcription start site; CTCF, CCCTC 
binding factor; DGF, digital genomic footprint; TFBS, transcription factor binding site; DHS, DNase I hypersensitivity site.
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Table 1 | Exonic nonsynonymous variants in the genomic loci associated with neuroticism and in LD (r2 > 0.6) with one of the 
independent genome-wide significant SNPs
rsiD Exon Gene A1 MAF GWAS P z score r2 independent 
significant 
SNP
Locus CADD RDB Minimum 
chromatin 
state
rs41266050 14 RABGAP1L T 0.25 5.65 ×  10–6 –4.54 0.84 rs7536102 6 2.85 7 5
rs34605051 10 KDM3A T 0.16 1.64 ×  10–7 –5.24 0.99 rs11127043 14 13.85 4 4
rs2073498 3 RASSF1 A 0.11 2.71 ×  10–8 5.56 0.98 rs6776145 25 19.43 7 3
rs4434138 62 STAB1 A 0.46 3.10 ×  10–7 5.12 0.93 rs2015971 26 5.48 5 4
rs66782572 1 NT5DC2 A 0.46 2.65 ×  10–6 4.70 0.67 rs2015971 26 0.00 4 1
rs11177 3 GNL3 A 0.38 2.49 ×  10–7 –5.16 0.75 rs2015971 26 22.90 1 d 1
rs2289247 11 GNL3 A 0.41 2.28 ×  10–6 –4.73 0.65 rs2015971 26 12.82 1 f 3
rs6617 1 SPCS1 C 0.41 1.96 ×  10–6 4.76 0.65 rs2015971 26 0.00 1 f 1
rs1029871 5 NEK4 C 0.38 2.29 ×  10–7 –5.17 0.75 rs2015971 26 24.10 1 f 2
rs678 12 ITIH1 A 0.36 1.44 ×  10–6 4.82 0.65 rs2015971 26 25.90 1 f 2
rs1042779 12 ITIH1 A 0.37 6.09 ×  10–6 4.52 0.63 rs2015971 26 0.15 1 f 2
rs198844 1 HIST1H1T C 0.47 3.07 ×  10–8 –5.54 0.98 rs198825 45 0.10 1 f 5
rs200484 1 HIST1H2BL A 0.13 1.53 ×  10–7 5.25 0.61 rs200965 46 2.68 1 f 1
rs240780 39 ASCC3 C 0.43 3.01 ×  10–8 5.54 0.96 rs240769 49 19.95 7 4
rs3173615 6 TMEM106B C 0.41 2.08 ×  10–8 –5.61 0.67 rs11509880 51 21.40 6 4
rs11765552 11 LMTK2 A 0.46 7.68 ×  10–8 5.38 0.98 rs34320230 55 12.24 6 4
rs10821128 3 FAM120AOS T 0.33 2.73 ×  10–9 5.95 0.99 rs10821129 71 0.05 4 4
rs41274386 2 FAM120AOS T 0.08 1.10 ×  10–7 5.31 0.66 rs78046549 71 2.36 4 1
rs1055710 1 FAM120AOS A 0.33 1.11 ×  10–9 –6.09 0.99 rs10821129 71 0.05 4 1
rs3816614 33 LRP4 T 0.23 5.69 ×  10–7 5.00 0.90 rs7940441 84 22.70 NA 4
rs2030166 5 NDUFS3 T 0.35 2.02 ×  10–10 –6.36 0.93 rs11039389 84 3.13 6 4
rs1064608 13 MTCH2 C 0.35 1.15 ×  10–10 –6.45 0.93 rs11039389 84 25.40 6 4
rs12286721 13 AGBL2 A 0.45 7.81 ×  10–8 –5.37 0.78 rs7107356 84 14.22 1 f 5
rs3816605 5 NUP160 T 0.46 5.68 ×  10–8 –5.43 0.75 rs7107356 84 6.61 6 4
rs4926 7 SERPING1 A 0.27 6.12 ×  10–7 4.99 0.86 rs73480560 85 23.50 5 4
rs11604671 6 ANKK1 A 0.49 2.57 ×  10–10 –6.32 0.64 rs2186800 88 1.39 5 4
rs2734849 8 ANKK1 A 0.49 8.43 ×  10–10 6.14 0.64 rs2186800 88 0.00 3a 4
rs1800497 8 ANKK1 A 0.20 8.45 ×  10–6 4.45 0.69 rs11214607 88 0.81 4 4
rs3825393 30 MYO1H T 0.36 2.95 ×  10–7 –5.13 0.79 rs2111216 94 10.93 1 f 4
rs2058804 2 KCTD10 A 0.48 1.82 ×  10–10 –6.38 0.76 rs2111216 94 2.11 6 4
rs7298565 12 UBE3B A 0.48 2.24 ×  10–10 6.34 0.76 rs2111216 94 22.70 6 4
rs9593 9 MMAB A 0.48 8.54 ×  10–10 –6.14 0.76 rs2111216 94 0.53 1 f 4
rs8007859 7 EXD2 T 0.39 2.28 ×  10–8 5.59 0.80 rs1275411 108 3.95 5 4
rs2286913 4 RPS6KL1 A 0.37 1.46 ×  10–7 5.26 0.89 rs3213716 110 12.96 5 2
rs7156590 3 RPS6KL1 T 0.37 2.79 ×  10–7 5.14 0.86 rs3213716 110 19.46 5 4
rs35755513 – CSNK1G1 T 0.07 2.87 ×  10–8 5.55 1.00 rs35755513 114 23.90 4 1
rs12443627 1 ENSG00000268863 C 0.37 1.28 ×  10–10 6.43 0.77 rs3751855 119 3.58 2b 1
rs9938550 7 HSD3B7 A 0.37 1.48 ×  10–10 –6.41 0.79 rs3751855 119 0.04 1d 3
rs35713203 1 ZNF646 C 0.38 3.67 ×  10–11 –6.62 0.98 rs3751855 119 0.05 2b 3
rs7196726 1 ZNF646 A 0.38 1.29 ×  10–11 –6.77 1.00 rs3751855 119 0.00 2b 3
rs7199949 8 PRSS53 C 0.38 1.32 ×  10–11 –6.77 1.00 rs3751855 119 0.00 2b 2
rs3803704 3 CMTR2 T 0.25 7.14 ×  10–8 –5.39 0.97 rs1424144 121 0.07 6 4
rs3748400 12 ZCCHC14 T 0.23 8.83 ×  10–9 –5.75 0.98 rs2042395 122 24.00 5 4
rs12949256 1 ARHGAP27 T 0.19 1.47 ×  10–23 10.00 0.73 rs77804065 126 11.97 4 1
rs16940674 6 CRHR1 T 0.23 5.24 ×  10–29 11.18 0.97 rs77804065 126 12.86 1 f 5
rs16940681 13 CRHR1 C 0.23 2.18 ×  10–30 11.46 0.97 rs77804065 126 1.76 4 5
Continued
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P = 1.27 × 10−6), and trimethylated Lys4 on histone H3 (H3K4me3; 
enrichment = 2.14, P = 1.02 × 10−5) and acetylated Lys9 on histone 
H3 (H3K9ac; enrichment = 2.17, P = 3.06 × 10−4) regions (Fig.  1d 
and Supplementary Table 13).
Polygenic scores (PGSs) calculated using PRSice23 (clump-
ing followed by P-value thresholding) and LDpred24 in three 
randomly drawn hold-out samples (UKB only, n = 3,000 each; 
Methods) explained up to 4.2% (P = 1.39 × 10−30) of the variance 
in neuroticism (Supplementary Fig.  4, Supplementary Table  14, 
and Supplementary Note). Although the current sample size is 
considered to be large for GWAS and PGSs can be calculated with 
relatively low standard errors, the variance explained by all SNPs 
combined in the PGSs was still relatively small, although this was 
not unexpected given the hSNP
2  of 10%. Our current results thus have 
little predictive power in independent samples, mostly owing to the 
low average effect sizes of contributing SNPs, and indicate that the 
genetic architecture of neuroticism is extremely polygenic. We do 
note that our current meta-analysis did not include possible genetic 
interactions (as even with the current sample sizes power would be 
limited) but that adding these in the future may increase the predic-
tive value of PGSs for neuroticism.
We used four strategies to link our SNP results to genes: posi-
tional, expression quantitative trait locus (eQTL), and chroma-
tin interaction mapping (Methods) and genome-wide gene-based 
association study (GWGAS, using MAGMA25). GWGAS evaluates 
the joint association effect of all SNPs within a gene to yield a gene-
based P value. Basesd on our meta-analysis results, 283 genes were 
implicated through positional mapping, 369 were implicated through 
eQTL mapping, and 119 were implicated through chromatin inter-
action mapping (Fig.  2a and Supplementary Table  15). GWGAS 
identified 336 genome-wide significant genes (P < 2.75 × 10−6; 
Fig.  2b,c, Supplementary Table  16, and Supplementary Note), of 
which 203 overlapped with genes implicated by FUMA, resulting 
in 599 unique neuroticism-related genes. Of these, 50 were impli-
cated by all four methods, of which 49 had chromatin interaction 
and eQTL associations in the same tissue or cell type (Fig. 2a and 
Supplementary Table 15).
Nineteen of the 119 genes implicated through chromatin inter-
action mapping are especially notable, as they were implicated via 
interactions between two independent genome-wide significant 
genomic risk loci. There were several chromatin interactions in 
seven tissue types (aorta, hippocampus, left ventricle, right ventricle, 
liver, spleen, and pancreas) across two risk loci on chromosome 6 
(Fig. 3a). Two genes are present in locus 45 and were mapped by 
chromatin interactions from risk locus 46 (HFE and HIST1H4C), 
and 16 genes encode histones in locus 46 and were mapped by 
interactions from locus 45 (Supplementary Table  15). One gene, 
XKR6, located on chromosome 8 in risk locus 61 is implicated by 
rsiD Exon Gene A1 MAF GWAS P z score r2 independent 
significant 
SNP
Locus CADD RDB Minimum 
chromatin 
state
rs62621252 1 SPPL2C T 0.23 9.05 ×  10–31 –11.53 0.97 rs77804065 126 0.00 5 5
rs242944 1 SPPL2C A 0.44 2.88 ×  10–12 –6.98 1.00 rs242947 126 0.00 5 5
rs62054815 1 SPPL2C A 0.23 1.74 ×  10–30 11.48 0.97 rs77804065 126 0.00 5 5
rs12185233 1 SPPL2C C 0.23 6.76 ×  10–29 11.16 0.96 rs77804065 126 25.60 1 f 5
rs12185268 1 SPPL2C A 0.23 4.08 ×  10–30 –11.40 0.97 rs77804065 126 0.00 1 f 5
rs12373123 1 SPPL2C T 0.23 7.80 ×  10–29 –11.14 0.97 rs77804065 126 22.70 1 f 5
rs12373139 1 SPPL2C A 0.23 2.19 ×  10–30 11.46 0.97 rs77804065 126 0.53 1 f 5
rs12373142 1 SPPL2C C 0.22 2.60 ×  10–28 –11.04 0.97 rs77804065 126 0.12 1 f 5
rs754512 1 MAPT A 0.23 1.17 ×  10–28 –11.11 0.97 rs77804065 126 2.39 1d 4
rs63750417 6 MAPT T 0.23 4.89 ×  10–30 11.39 0.97 rs77804065 126 8.68 5 4
rs62063786 6 MAPT A 0.23 1.05 ×  10–29 11.32 0.97 rs77804065 126 7.65 5 4
rs62063787 6 MAPT T 0.23 4.57 ×  10–30 –11.39 0.97 rs77804065 126 0.00 5 4
rs17651549 6 MAPT T 0.23 1.11 ×  10–28 11.11 0.97 rs77804065 126 34.00 1 f 4
rs10445337 8 MAPT T 0.23 1.41 ×  10–28 –11.09 0.96 rs77804065 126 9.93 1 f 4
rs62063857 1 STH A 0.23 3.71 ×  10–30 –11.41 0.97 rs77804065 126 0.00 7 4
rs34579536 15 KANSL1 A 0.23 1.92 ×  10–30 –11.47 0.96 rs77804065 126 8.02 3a 3
rs34043286 8 KANSL1 A 0.23 3.14 ×  10–30 –11.43 0.97 rs77804065 126 15.71 4 4
rs4969391 14 BAIAP2 A 0.16 1.69 ×  10–14 7.67 0.90 rs56084168 128 12.58 4 4
rs2282632 11 ASXL3 A 0.50 3.37 ×  10–8 –5.52 0.73 rs10460051 129 1.54 6 4
rs7232237 12 ASXL3 A 0.50 1.59 ×  10–8 –5.65 0.84 rs10460051 129 0.00 5 4
rs17522826 1 TCF4 A 0.18 2.17 ×  10–10 6.35 0.60 rs10503002 133 14.22 5 1
rs20551 15 EP300 A 0.29 3.44 ×  10–18 –8.70 0.98 rs9611519 138 3.23 5 4
rs139431 2 L3MBTL2 T 0.37 9.45E ×  10–7 –4.90 0.63 rs7289932 138 10.26 7 4
rs739134 2 C22orf46 T 0.19 4.55 ×  10–7 5.04 0.61 rs761366 138 22.60 1 f 4
SNP P values and z scores were computed in METAL by a weighted z-score method (two-sided test). Per-SNP n values are reported in Supplementary Table 2 (for genome-wide significant SNPs) and in 
the publicly available summary statistics. rsID, rs number of the ExNS SNP; Exon, exon in which the SNP is located; Gene, nearest gene; A1, effect allele; MAF, minor allele frequency; GWAS P, SNP P value 
in the GWAS meta-analysis; z score, z score from the GWAS meta-analysis; r2, maximum r2 of the SNP with one of the independent significant SNPs; Locus, index of the genomic risk locus; CADD, CADD 
score; RDB, RegulomeDB score; Minimum chromatin state, minimum chromatin state of the SNP. Results are reported on hg19 coordinates (GRCh37); NA, not available in RegulomeDB (alleles do not 
match). Genes containing multiple ExNS SNPs are annotated in bold.
Table 1 | Exonic nonsynonymous variants in the genomic loci associated with neuroticism and in LD (r2 > 0.6) with one of the 
independent genome-wide significant SNPs (Continued)
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chromatin interactions in five tissue types (aorta, left ventricle, 
liver, pancreas, and spleen), including cross-locus interactions from 
locus 60 (Fig. 3b and Supplementary Table 15). This gene was also 
mapped by eQTLs in blood and transformed fibroblasts. Of the 19 
genes mapped by two loci, 4 were located outside of the risk loci 
(HIST1H2AI, HIST1H3H, HIST1H2AK, and HIST1H4L) and 7 were 
also implicated by eQTLs in several tissue types (HFE in subcutane-
ous adipose, aorta, esophagus muscularis, lung, tibial nerve, sun-
exposed skin, and thyroid; HIST1H4J in blood and adrenal gland; 
and HIST1H4K, HIST1H2AK, HIST1H2BO, and XKR6 in blood).
We used the gene-based P values for gene set analysis in MAGMA25 
and tested 7,246 predefined gene sets derived from MSigDB26, gene 
expression profiles in 53 tissue types obtained from the Genotype-
Tissue Expression (GTEx) Project27, and 24 cell-type-specific expres-
sion profiles using RNA-seq information28 (Methods). Neuroticism 
was significantly associated with genes predominantly expressed in 
six brain tissue types (Fig. 2d and Supplementary Tables 17 and 18) 
and with seven Gene Ontology (GO) gene sets, with the strongest 
association for neurogenesis (P = 4.43 × 10−9) and neuron differ-
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Fig. 2 | Mapping of genes and tissue expression and cell expression profiles. a, Venn diagram showing overlap of genes implicated by positional mapping, 
eQTL mapping, chromatin interaction mapping, and GWGAS. b, Quantile–quantile plot of GWGAS (n =  449,484 individuals). Gene P values were 
computed using MAGMA’s gene-based test. c, Manhattan plot of the GWGAS on neuroticism (n =  449,484 individuals). Gene P values were computed 
using MAGMA’s gene-based test. The y axis shows the –log10-transformed P value of each gene, and the x axis shows the chromosomal position  
(start position). The upper dashed line indicates the threshold for genome-wide significance of the gene-based test (P <  2.76 ×  10−6; 0.05/18,128), and 
the lower dashed line indicates the suggestive threshold (P <  2.76 ×  10−5; 0.5/18,128). d, Gene expression profiles of identified genes for 53 tissue types. 
Expression data were extracted from the GTEx database. Expression values (Reads Per Kilobase Million - RPKM) were log2 transformed with pseudocount 1 
after Winsorization at 50 and averaged per tissue. Gene set tests for tissue expression were calculated with MAGMA (Methods). e, Enrichment of genetic 
signal for neuroticism in 24 cell types derived from mouse brain (Methods). The dashed line indicates the Bonferroni-corrected significance threshold 
(P =  0.05/7,323 =  6.83 ×  10−6).
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gene set analyses (Methods) suggested that three of the seven gene 
sets (neurogenesis, P = 4.43 × 10−9; behavioral response to cocaine, 
P = 1.84 × 10−7; axon part, P = 5.26 × 10−8) had largely indepen-
dent associations, implying a role in neuroticism (Supplementary 
Table  19). Conditional analyses of the tissue-specific expression 
ascertained general involvement of (frontal) cortex–expressed genes 
(Supplementary Fig. 5 and Supplementary Table 20).
Cell-type-specific gene set analysis showed significant asso-
ciation with genes expressed in multiple mouse-derived brain 
cell types (Fig. 2e, Methods, and Supplementary Table 21), with 
dopaminergic neuroblasts (P = 3.49 × 10−8), medium spiny neu-
rons (P = 4.23 × 10−8), and serotonergic neurons (P = 1.37 × 10−7) 
showing the strongest associations. Conditional analysis indicated 
that these three cell types were also independently associated 
with neuroticism.
With the aim to further specify neuroticism’s neurobiological 
interpretation, we compared the genetic signal of the full neuroti-
cism trait to that of two genetically distinguishable neuroticism 
subclusters, ‘depressed affect’ and ‘worry’ (Methods), which we had 
previously established through hierarchical clustering of the genetic 
correlations between the 12 neuroticism items13. As a validation of 
the depressed affect dimension, we also compared the genetic sig-
nal of neuroticism and the two subclusters to that of depression. 
Genome-wide association analyses of the subclusters were con-
ducted on the UKB data only (dictated by item-level data availabil-
ity (Methods); depressed affect, n = 357,957; worry, n = 348,219). 
For depression, our meta-analysis comprised data from the UKB14 
(n = 362,696; Supplementary Fig.  6), 23andMe15 (n = 307,354), 
and the Psychiatric Genetics Consortium (PGC29; n = 18,759) 
(total n = 688,809, which is the largest n for depression thus far; 
rg between samples: 0.61–0.80; Methods and Supplementary 
Table 22; see the Supplementary Note for details on the depression 
GWAS results). Genetic correlations of neuroticism with all three 
phenotypes were considerable (depression, rg = 0.79; depressed 
affect, rg = 0.88; worry, rg = 0.87; Supplementary Table 23). The posi-
tive genetic correlations between neuroticism and depression might 
in part be due to overlap in item content between the instruments 
used to gauge these phenotypes, reducing their operational distinct-
ness13.
The subclusters showed notable differences in genetic signal 
(for example, exclusive genome-wide significant associations on 
chromosomes 2 and 19 for depressed affect and on chromosomes 
3 and 22 for worry; Supplementary Figs. 7–13 and Supplementary 
Tables 24–26). Of the 136 genetic loci associated with neuroticism, 
32 were also genome-wide significant for depressed affect (7 shared 
with depression) but not for worry, and 26 were also genome-wide 
significant for worry (3 shared with depression) but not for depressed 
affect (Supplementary Fig. 13 and Supplementary Table 27). These 
results were mirrored by gene-based analyses (Supplementary 
Fig.  14, Supplementary Tables  28–30, and Supplementary Note), 
suggesting that part of neuroticism’s genetic signal originated spe-
cifically in one of the two subclusters, possibly implicating different 
causal genetic mechanisms. To further verify the biological distinct-
ness of the two clusters, cluster-specific functional annotation was 
conducted, which demonstrated that, with respect to SNPs that were 
highly likely to have functional consequences (ExNS), the clusters 
were (i) distinct and (ii) adding information to the results of neurot-
icism sum-score analysis (Supplementary Fig.  15, Supplementary 
Tables 31–34, and Supplementary Note).
To test whether the signal of the gene sets implicated in neuroti-
cism originated from one of the specific subclusters, we conducted 
conditional analyses, correcting neuroticism for depressed affect and 
worry scores separately (Supplementary Fig. 16 and Supplementary 
Table 35). The association with axon part was markedly lower after 
correction for worry scores (uncorrected, P = 5.26 × 10−8; corrected 
for depressed affect, P = 2.42 × 10−6; corrected for worry, P = 0.0013), 
suggesting that the involvement of axon part in neuroticism origi-
nates predominantly from the worry component.
To examine the genetic correlational pattern of neuroticism and 
to compare it to the patterns observed for depression, depressed 
affect, and worry, we used LDSC18,30 to calculate genetic correlations 
with 35 traits for which large-scale GWAS summary statistics were 






































































































































































































































































Fig. 3 | Genomic risk loci, eQTL associations, and chromatin 
interactions for chromosomes 6 and 8, containing cross-locus 
interactions. Circos plots showing genes on chromosome 6 (a) and 
chromosome 8 (b) that were implicated through the genomic risk loci 
(blue areas) by positional mapping, by chromatin interaction mapping 
(CTI; orange font), eQTL mapping (green font), or by both chromatin 
interaction and eQTL mapping (red font). The outer layer shows a 
Manhattan plot containing the –log10-transformed P value of each SNP 
in the GWAS meta-analysis of neuroticism (n =  449,484 individuals). 
Empty regions in the Manhattan plot layer indicate regions where no 
SNPs with P <  0.05 were situated.
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Bonferroni-corrected significant genetic correlations between neu-
roticism and other traits (α = 0.05/(4 × 35); P < 3.6 × 10−4) (Fig.  4 
and Supplementary Table  37), which covered previously reported 
psychiatric traits (rg range: 0.20 to 0.82) and subjective well-being 
(rg = –0.68). These correlations were supported by enrichment 
of genes associated with neuroticism in sets of genes that had 
previously been implicated in psychiatric traits (Supplementary 
Table 38). The rg values of depression and depressed affect strongly 
mirrored each other (the correlation between their rg values was 
r = 0.98; Supplementary Note), which validated the depressed affect 
cluster. The correlational patterns for depressed affect and worry 
were markedly different (for example, anorexia nervosa, schizo-
phrenia, and ever-smoker) and sometimes in opposite directions 
(for example, body mass index (BMI)). The genetic correlations of 
the full neuroticism trait seemed to be a mix of the genetic signal of 
both clusters, with neuroticism’s rg values generally in between the 
cluster-specific rg values.
To investigate whether these genetic correlations reflected direc-
tional effects, we performed Mendelian randomization (MR) analy-
sis using the GSMR package31 (Methods). Among other things, we 
observed unidirectional effects of BMI on depression and depressed 
affect (bxy = 0.061, P = 4.96 × 10−12 and bxy = 0.049, P = 5.35 × 10−6, 
respectively) and bidirectional associations between neuroticism 
and depression, as well as between all four main traits and sub-
jective well-being, cognition, and several psychiatric disorders 
(Supplementary Table 39 and Supplementary Note).
We aimed to identify gene–drug interactions (using the Drug 
Gene Interaction database (DGIdb)32,33; Methods) of genes iden-
tified for each of the four traits, and we observed a large number 
of potential targets for pharmacotherapeutic intervention that 
were either shared between traits or distinct for each phenotype 
(Supplementary Fig.  17, Supplementary Tables  40 and 41, and 
Supplementary Note).
In conclusion, we identified 124 new genetic loci for neuroti-
cism (73 taking into account a simultaneously conducted study by 
Luciano et al.34; Supplementary Table 42 and Supplementary Note). 
Extensive functional annotations highlighted several genes impli-
cated through multiple routes. We demonstrated the involvement 
of specific neuronal cell types and three independently associated 
genetic pathways, and we established the genetic multidimensional-
ity of the neuroticism phenotype and its link with depression. The 
current study provides new leads and testable functional hypotheses 
for unraveling the neurobiology of neuroticism, its subtypes, and its 
genetically associated traits.




github.com/bulik/ldsc; FUMA, http://fuma.ctglab.nl/; GSMR, 
http://cnsgenomics.com/software/gsmr/; DGIdb, http://dgidb.org/; 
Ethical and Independent Review Services, http://www.eandireview.
com/; Genetics of Personality Consortium, http://www.tweelingen-
register.org/GPC/; Psychiatric Genomics Consortium, http://www.
med.unc.edu/pgc/results-and-downloads; GTEx Portal, https://
www.gtexportal.org/home/; GWAS summary statistics https://ctg.
cncr.nl/software/summary_statistics.
Methods
Methods, including statements of data availability and any asso-
ciated accession codes and references, are available at https://doi.
org/10.1038/s41588-018-0151-7.
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Methods
Samples. UK Biobank. The UKB study is a major data resource that contains 
genetic, as well as a wide range of phenotypic, data of ~500,000 participants aged 
39–73 years at recruitment14. We used data released in July 2017, and selection 
(discussed below) resulted in final sample sizes of n = 372,903 and n = 362,696 
individuals for neuroticism and depression, respectively (Supplementary Note). 
The UKB received ethical approval from the National Research Ethics Service 
Committee North West–Haydock (reference 11/NW/0382), and all study 
procedures were performed in accordance with the World Medical Association for 
medical research. The current study was conducted under UKB application 16406.
23andMe. 23andMe, Inc., is a large personal genomics company that provides 
genotype and health-related information to customers. For the neuroticism 
and depression meta-analyses, we used neuroticism and depression GWAS 
summary statistics, respectively, from a subset of 23andMe research participants 
(neuroticism, n = 59,206; depression, n = 307,354), which is described in more 
detail elsewhere10,35. All included participants provided informed consent and 
were of European ancestry, and related individuals were excluded. Online data 
collection procedures were approved by the Ethical and Independent Review 
Services (E&I Review), an AAHRPP-accredited private institutional review board 
(see URLs).
Genetics of Personality Consortium. The GPC is a large collaboration concerning 
GWAS on personality. We used summary statistics of neuroticism from the first 
GPC personality meta-analysis (GPC1; see URLs)9 on ten discovery cohorts 
(SardiNIA, NTR/NESDA, ERF, SAGE, HBCS, NAG, IRPG, QIMR, LBC1936, 
BLSA, and EGPUT), which included in total n = 17,375 participants of European 
descent. All included studies were approved by local ethics committees, and 
informed consent was obtained from all of the participants.
Psychiatric Genetics Consortium. The PGC unites investigators worldwide to 
conduct genetic meta- and mega-analyses for psychiatric disorders. We used 
summary statistics from the latest published PGC meta-analysis on depression 
(see URLs)29, which included data from eight cohorts (Bonn-Mannheim, GAIN, 
GenRED, GSK, MDD2000, MPIP, RADIANT, and STAR*D), which covered 
n = 18,759 participants of European descent. All included studies were approved 
by local ethics committees, and informed consent was obtained from all  
of the participants.
Phenotype assessment: neuroticism. UK Biobank. Neuroticism was measured 
with 12 dichotomous (yes or no) items of the Eysenck Personality Questionnaire 
Revised Short Form (EPQ-RS)36, using a touchscreen-based questionnaire at the 
UKB assessment centers (Supplementary Note). Participants with valid responses 
to < 10 items were excluded from analyses. A weighted neuroticism sum-score 
was calculated by adding up individual valid item responses and dividing that sum 
by the total number of valid responses. In addition, we constructed two scores 
based on subsets of genetically homogeneous neuroticism items, as established 
previously13 through hierarchical clustering analysis of the genetic correlations 
between the 12 neuroticism items (Supplementary Note). Specifically, the sum of 
scores on four EPQ-RS items (i.e., “Do you often feel lonely?”, “Do you ever feel 
‘just miserable’ for no reason?”, “Does your mood often go up and down?”, and  
“Do you often feel ‘fed up’?”) was used to obtain scores for the cluster depressed 
affect. Similarly, the sum of scores on four other EPQ-RS items (i.e., “Are you 
a worried?”, “Do you suffer from nerves?”, “Would you call yourself a nervous 
person?”, and “Would you call yourself tense or highly strung”) was used to obtain 
scores for the cluster worry. In the item-cluster analyses, only participants with 
complete scores on all four items were included, which resulted in n = 357,957 and 
n = 348,219 for depressed affect and worry, respectively.
23andMe. Neuroticism was operationalized as the sum of eight neuroticism items 
(five-point Likert scale: from ‘disagree strongly’ to ‘agree strongly’) from the Big 
Five Inventory (BFI)37,38, as obtained in an online survey. Only participants with 
valid responses to all items were included in the analyses (Supplementary Note).
Genetic Personality Consortium. All ten cohorts included in the first meta-analysis 
of the GPC used sums of the scores on 12 items (five-point Likert scale: from 
‘strongly disagree’ to ‘strongly agree’) of the NEO-FFI39 to measure neuroticism. 
If < 4 item scores were missing, data on invalid items were imputed by taking an 
individual’s average score on valid items. Participants were excluded from analyses 
if they had invalid scores on > 3 items9 (Supplementary Note).
Phenotype assessment: depression. UK Biobank. Depression was operationalized 
by adding up the scores on two continuous items (“Over the past two weeks, 
how often have you felt down, depressed or hopeless?” and “Over the past two 
weeks, how often have you had little interest or pleasure in doing things?”; both 
were evaluated on a four-point Likert scale: from ‘not at all’ to ‘nearly every day’), 
resulting in a continuous depression score (as used previously12). Only participants 
with scores on both items were included in the analyses, which resulted in 
n = 362,696 (Supplementary Note).
23andMe. This concerns a case–control sample. Four self-report survey items were 
used to determine case–control status. Cases were defined as replying affirmatively 
to at least one of these questions and not replying negatively to previous ones. 
Controls replied negatively to at least one of the questions and did not report being 
diagnosed with depression on previous ones (Supplementary Note).
Psychiatric Genetics Consortium. This concerns a case–control sample. Cases 
had a DSM-IV lifetime (sometimes (early-onset) recurrent) major depressive 
disorder (MDD) diagnosis, which was established through either structured 
diagnostic interviews or clinician-administered DSM-IV checklists. Most 
cases were ascertained from clinical sources, whereas controls were randomly 
selected from population resources and screened for a lifetime history of MDD29 
(Supplementary Note).
Genotyping and imputation. UK Biobank: neuroticism. We used genotype data 
released by the UKB in July 2017. The genotype data collection and processing are 
described in detail by the responsible UKB group14. In short, 489,212 individuals 
were genotyped on two customized SNP arrays (the UK BiLEVE Axiom array 
(n = 50,520) and the UK Biobank Axiom array (n = 438,692)), which covered 
812,428 unique genetic markers (95% overlap in SNP content). After quality-
control procedures14, 488,377 individuals and 805,426 genotypes remained. 
Genotypes were phased and imputed by the coordinating team to approximately 96 
million genotypes by using a combined reference panel, including the Haplotype 
Reference Consortium and the UK10K haplotype panel. Imputed and quality-
controlled genotype data were available for 487,422 individuals and 92,693,895 
genetic variants. As recommended by the UKB team, variants imputed from the 
UK10K reference panel were removed from the analyses due to technical errors in 
the imputation process.
In our analyses, only individuals of European descent (based on genetic 
principal components) were included. Therefore, principal components from the 
1000 Genomes reference populations40 were projected onto the called genotypes 
available in UKB. Subjects were identified as European if their projected principal-
component score was closest (based on Mahalanobis distance) to the average score 
of the European 1000 Genomes sample41. European subjects with a Mahalanobis 
distance > 6 s.d. were excluded. In addition, participants were excluded based on 
withdrawn consent, UKB-provided relatedness (subjects with the most inferred 
relatives, third degree or closer, were removed until no related subjects were 
present), discordant sex, and sex aneuploidy. After selecting individuals based 
on available neuroticism sum-score and active consent for participation, 372,903 
individuals remained for the analyses.
To correct for population stratification, 30 principal components were 
calculated on the subset of quality-controlled unrelated European subjects based 
on 145,432 independent (r2 < 0.1) SNPs with MAF > 0.01 and INFO = 1 using 
FlashPC242. Subsequently, imputed variants were converted to a hard call by using 
a certainty threshold of 0.9. Multiallelic SNPs, indels, and SNPs without unique 
rs identifiers were excluded, as well as SNPs with a low imputation scores (INFO 
score < 0.9), low MAF ( < 0.0001), and high missingness ( > 0.05). This resulted in a 
total of 10,847,151 SNPs that were used for downstream analysis.
UK Biobank: depression. A genotyping, imputation, and filtering procedure similar 
to the one described above for the UKB neuroticism GWAS was used for the UKB 
depression GWAS, which resulted in n = 362,696.
Genome-wide association analyses. UK Biobank: neuroticism. Genome-wide 
association analyses were performed in PLINK43,44, using a linear regression model 
of additive allelic effects with age, sex, Townsend deprivation index, genotype 
array, and ten genetic European-based principal components as covariates 
(Supplementary Note).
UK Biobank: depression, depressed affect, and worry. The settings, covariates, and 
exclusion criteria for the UKB depression, UKB depressed affect, and UKB worry 
GWAS were the same as those described above for the UKB neuroticism GWAS, 
with 10,847,151 SNPs remaining after all exclusion steps (Supplementary Note).
Other samples. Summary statistics were used for 23andMe, GPC, and PGC.  
Details on the genome-wide association analyses of these samples can be found 
elsewhere (23andMe neuroticism10; 23andMe depression35; GPC neuroticism9;  
PGC depression29).
Meta-analysis. To maximize the statistical power to detect associated genetic 
variants of small effect, we conducted meta-analyses for both neuroticism and 
depression17 (Supplementary Note). All meta-analyses were performed in METAL16.
Neuroticism. The meta-analysis of the neuroticism GWAS in UKB, 23andMe, and 
GPC was performed on the P value of each SNP by using a two-sided sample-size-
weighted fixed-effects analysis. Bonferroni correction was applied to correct for 
multiple testing. The genetic signal correlated strongly between the three samples 
(rg range: 0.83 to 1.07; Supplementary Table 1), supporting the decision to use 
meta-analysis.
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Depression. Because the UKB GWAS concerned a continuous operationalization 
of the depression phenotype, whereas 23andMe and PGC used case–control 
phenotypes, the odds ratios from the 23andMe and PGC summary statistics were 
converted to log odds, which reflected the direction of the effect. The meta-analysis 
was then performed on the P value of each SNP by using a two-sided sample-size-
weighted fixed-effects analysis. Bonferroni correction was applied to correct for 
multiple testing. Genetic correlations between the three samples were moderate to 
strong (rg range: 0.61 to 0.80; Supplementary Table 22).
Genomic risk loci and functional annotation. Functional annotation was 
performed with FUMA17 (see URLs), an online platform for functional mapping 
of genetic variants. We first defined independent significant SNPs, which had 
a genome-wide significant P value (5 × 10−8) and were independent at r2 < 0.6. 
A subset of these independent significant SNPs, which were independent from 
each other at r2 < 0.1, was marked as lead SNPs (based on LD information from 
UKB genotypes; see the Supplementary Note for a more detailed explanation). 
Subsequently, genomic risk loci were defined by merging lead SNPs that physically 
overlapped or for which LD blocks were less than 250 kb apart. Note that when 
analyzing multiple phenotypes, as in the current study, a locus may be discovered 
for different phenotypes while different lead SNPs are identified.
All SNPs in the meta-analysis results that were in LD (r2 > 0.6) with one of 
the independent significant SNPs and that had P < 1.0 × 10−5 and MAF > 0.0001 
were selected for annotation. The rationale behind this inclusive approach was 
that the most significant SNP in the locus was not necessarily the causal SNP 
but that it might be in LD with the causal SNP. We thus annotated all SNPs in 
LD with the most significant SNP to get insight into the possible biological 
reasons for observing a statistical association. We note that liberalizing the r2 and 
P-value thresholds can dilute the functional annotation results, whereas more 
stringent thresholds may result in exclusion of possibly interesting functional 
variants. Functional consequences for these SNPs were obtained by performing 
ANNOVAR45 gene-based annotation using Ensembl genes. In addition, CADD 
scores (indicating the deleteriousness of a SNP, with scores > 12.37 seen as likely 
deleterious21) and RegulomeDB scores46 (for which a higher probability of having 
a regulatory function is indicated by a lower score) were annotated to SNPs by 
matching chromosome, position, reference, and alternative alleles. CADD scores 
integrate a number of diverse annotations into a single measure that correlates with 
pathogenicity, disease severity, and experimentally measured regulatory effects and 
complex trait associations21.
Gene mapping. SNPs in genomic risk loci that were genome-wide significant or 
were in LD (r2 > 0.6) with one of the independent significant SNPs were mapped to 
genes in FUMA20 using one of three strategies.
First, positional mapping uses the physical distances (i.e., within 10-kb 
windows) from known protein-coding genes in the human reference assembly 
(GRCh37 or hg19) to map SNPs to genes. The second strategy, eQTL mapping, 
uses information from three data repositories (GTEx, Blood eQTL browser, 
and BIOS QTL browser) and maps SNPs to genes based on a significant eQTL 
association (i.e., where the expression of the gene is associated with allelic variation 
at the SNP). eQTL mapping is based on cis-eQTLs, which can map SNPs to genes 
up to 1 Mb away. FUMA applied a false discovery rate (FDR) of 0.05 to define 
significant eQTL associations. Third, chromatin interaction mapping mapped 
SNPs to genes based on a significant chromatin interaction between a genomic 
region in a risk locus and promoter regions of genes (250 bp upstream and 500 bp 
downstream of a TSS). This type of mapping does not have a distance boundary  
(as in eQTL mapping) and may therefore involve long-range interactions. 
Currently, FUMA contains Hi-C data for 14 tissue types from the study of 
Schmitt et al.47. Notably, as chromatin interactions are usually defined in a certain 
resolution (in the current study, 40 kb), an interacting region may span several 
genes. Hence, this method would map all SNPs within these regions to genes in 
the corresponding interaction region. By integrating predicted enhancers and 
promoters in 111 tissue and cell types from the Roadmap Epigenomics Project48, 
we aimed to prioritize candidate genes from chromatin interaction mapping. Using 
this information, FUMA selected chromatin interactions for which one region 
involved in the interaction overlapped with predicted enhancers and the other 
overlapped with predicted promoters 250 bp upstream and 500 bp downstream of 
the TSS of a gene. Similar to eQTL mapping, we used an FDR of 1 × 10−5 to define 
significant interactions.
Gene-based analysis. GWGAS can identify genes in which multiple SNPs show 
moderate association to the phenotype of interest without reaching the stringent 
genome-wide significance level. At the same time, because GWGAS takes all SNPs 
within a gene into account, a gene harboring a genome-wide significant SNP may 
not be implicated by GWGAS analyses when multiple other SNPs within that gene 
show only very weak association signal. The P values from the SNP-based GWAS 
meta-analyses for neuroticism and depression, and the GWAS for depressed affect 
and worry, were used as input for the GWGAS in MAGMA (see URLs)25, and all 
19,427 protein-coding genes from the NCBI 37.3 gene definitions were used. We 
annotated all of the SNPs in our genome-wide association (meta-)analyses to these 
genes, resulting in 18,187, 18,187, 18,182, and 18,182 genes that were represented 
by at least one SNP in the neuroticism meta-analysis, the depression meta-analysis, 
the depressed affect GWAS, and the worry GWAS, respectively. We included a 
window around each gene of 2 kb before the TSS and 1 kb after the transcription 
stop site. Gene association tests were performed, taking into account the LD 
between SNPs, and a stringent Bonferroni correction was applied to correct for 
multiple testing (0.05/number of genes tested: P < 2.75 × 10−6).
Gene set analysis. We used MAGMA25 to test for association of predefined 
gene sets with neuroticism, depression, depressed affect, and worry. A total of 
7,246 gene sets were derived from several resources, including BioCarta, KEGG, 
Reactome49, and GO. All gene sets were obtained from MSigDB version 6.0 (see 
URLs). Additionally, we performed gene set analysis on 53 tissue expression 
profiles obtained from the GTEx portal (see URLs) and on 24 cell-type-specific 
expression profiles.
For all gene sets, we computed competitive P values, which result from testing 
whether the combined effect of genes in a gene set is significantly larger than the 
combined effect of the same number of randomly selected genes (in contrast to 
testing against the null hypothesis of no effect; self-contained test). Here we only 
report Bonferroni-corrected (α = 0.05/7,323 = 6.83 × 10−6) competitive P values, 
which were more conservative than the self-contained P values.
Cell-type-specific expression analysis. Definition and calculation of gene sets for 
cell-type-specific expression is described in detail elsewhere28,50. Briefly, brain-cell-
type expression data were drawn from single-cell RNA-seq (scRNA-seq) data from 
mouse brain28. For each gene, the value for each cell type was calculated by dividing 
the mean unique molecular identifier (UMI) counts for the given cell type by the 
summed mean UMI counts across all cell types28. MAGMA25 was used to calculate 
associations between gene-wise P values from the meta-analysis and cell-type-
specific gene expression. Genes were grouped into 40 equally sized bins by specificity 
of expression, and bin membership was subsequently regressed on gene-wise 
association with neuroticism in the meta-analysis. Results were deemed significant if 
the association P values were smaller than the relevant Bonferroni threshold.
Conditional gene set and tissue expression analyses. Conditional gene set 
analyses were performed using MAGMA25 to determine which tissue expression 
levels and MSigDB gene sets represented independent associations. In these 
regression-based analyses, the effect of a gene set (or tissue expression) of interest 
was conditioned on the effects of another gene set (or tissue expression) to correct 
the association of the tested gene set for any effect it shared with the conditioned-
on gene set.
For the MSigDB gene sets, we conducted two series of conditional analyses. 
First, we performed forward selection on the initially significant gene sets, in 
each step selecting the most strongly associated gene set after conditioning on all 
already-selected gene sets (Supplementary Table 19). Second, to test whether the 
association of gene sets to neuroticism was primarily driven by the association 
signal of one specific subcluster, we also re-ran the GO gene set analyses, 
conditioning on the gene z scores of depressed affect or worry (Supplementary 
Table 35). If the gene set association decreased after conditioning on one cluster 
but did not decrease or did so to a lesser extent when conditioned on the other, 
then this suggested that neuroticism’s association to that gene set was primarily 
driven by the genetic effects of the first, and not the second, item cluster.
Genetic correlations. Genetic correlation (rg) values were computed using LD 
Score regression18,30 (see URLs). The significance of the genetic correlations of 
neuroticism, depression, depressed affect, and worry with 35 behavioral, social, 
and (mental) health phenotypes for which summary statistics were available was 
determined by correcting for multiple testing through a stringent Bonferroni-
corrected threshold of P < 0.05/(4 × 35) = 3.6 × 10−4.
Mendelian randomization. We performed MR analysis to test whether genetic 
correlations could be explained by directional effects between traits. Generalized 
summary-data-based MR (GSMR)31, a summary-statistics-based MR method that 
uses independent genome-wide significant variants as instrumental variables, was 
used for MR analysis. Causal associations were tested between the 4 traits and 
the 21 traits that showed significant genetic correlations (rg values) in LD Score 
regression analysis with at least one of the 4 traits. To test for unidirectional and 
bidirectional effects, we performed both forward and reverse GSMR analyses (i.e., 
using the four GWAS traits either as predictor or as outcome). Associations were 
Bonferroni corrected for multiple testing with P < 0.05/(21 × 4 × 2) = 2.98 × 10−4.
Partitioned heritability. To investigate the relative contribution to the overall 
SNP-based heritability annotated to 22 specific genomic categories, we partitioned 
SNP heritability by binary annotations using stratified LD Score regression22. 
Information about binary SNP annotations was obtained from the LD Score 
website (see URLs). Enrichment results reflected the X-fold increase in h2 
proportional to the number of SNPs (for example, enrichment = 13.79 for SNPs 
in conserved regions implies that a 13.79-fold increase in h2 is carried by SNPs in 
these region, corrected for the proportion of SNPs in these regions compared to all 
tested SNPs).
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Gene drug targets. We aimed to identify potential druggable targets by searching 
for the implicated genes (by one of the gene-mapping strategies) in DGIdb32,33 
(version 3.0; see URLs). The DGIdb contains mined data from several resources 
and provides a comprehensive overview of the druggability of gene targets. First, 
we searched 20 drug–gene databases for interactions with existing medicines 
based on 48 known interaction types with genes that were implicated in each 
of the four phenotypes. Filtering was performed based on known interaction 
types and interactions with US Food and Drug Administration (FDA)-approved 
pharmaceutical compounds. Second, to identify genes that may form targets for 
novel therapies in addition to existing medicines, we searched for the potential 
gene druggability of gene targets and performed an additional search in ten DGIdb 
databases containing information about gene targetability.
Polygenic risk scoring. To test the predictive accuracy (Δ R2) of our meta-analysis 
results for neuroticism, we calculated a PGS based on the SNP effect sizes of 
the current analysis. For independent samples, we used three hold-out samples; 
we removed 3,000 individuals from the discovery sample (UKB only, as we had 
access only to individual-level data from this sample) and re-ran the genome-
wide analyses. We repeated this three times, to create three randomly drawn, 
independent hold-out samples. Next, we calculated a PGS on the individuals in 
each of the three hold-out samples. PGSs were calculated using LDpred24 and 
PRSice23 (clumping followed by P-value thresholding).
For LDpred, PGSs were calculated based on different LDpred priors 
(PLDpred = 0.01, 0.05, 0.1, 0.5, 1, and infinitesimal). The explained variance (R2) 
was derived from the linear model, using the neuroticism summary score as the 
outcome, while correcting for age, sex, array, Townsend deprivation index, and 
genetic principal components.
Reporting Summary. Further information on experimental design is available in 
the Nature Research Reporting Summary linked to this article.
Data availability. Our policy is to make genome-wide summary statistics 
(sumstats) publicly available. Sumstats from our neuroticism meta-analysis, our 
depression meta-analysis, and the genome-wide association analyses for depressed 
affect and worry are available for download at the website of the Department of 
Complex Trait Genetics, CNCR (see URLs).
Note that our freely available meta-analysis sumstats concern results excluding 
the 23andMe sample. This is a non-negotiable clause in the 23andMe data transfer 
agreement, which is intended to protect the privacy of the 23andMe research 
participants. To fully recreate our meta-analysis results for neuroticism (i) obtain 
the sumstats from Lo et al. (2017) for 23andMe (see below) and (ii) conduct 
a meta-analysis of our sumstats with those from Lo et al. To fully recreate our 
meta-analysis results for depression (i) obtain the sumstats from Hyde et al.35 for 
23andMe (see below) and (ii) conduct a meta-analysis of our sumstats with those 
for Hyde et al.35.
23andMe participant data are shared according to community standards 
that have been developed to protect against breaches of privacy. Currently, these 
standards allow for the sharing of summary statistics for at most 10,000 SNPs. The 
full set of summary statistics can be made available to qualified investigators who 
enter into an agreement with 23andMe that protects participant confidentiality. 
Interested investigators should contact David Hinds (dhinds@23andme.com) for 
more information.
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    Experimental design
1.   Sample size
Describe how sample size was determined. We made use of data collected by external sources (UK biobank, 23andMe, 
Genetics of Personality Consortium and the Psychiatric genetics Consortium). For 
all samples the sample size consists of all individuals that remain after quality 
control of the data and exclusion of withdrawn subjects. Detailed information on 
the samples used, as well as the exclusion/inclusion criteria, are provided in the 
Online Methods (sections: Samples, Genotyping and imputation, Genome-wide 
association analyses).
2.   Data exclusions
Describe any data exclusions. See Online Methods. 
For UKB data: we excluded participants from further analyses if they had excessive 
missing phenotypic data (section: Phenotype assessment), did not pass standard 
quality control or withdrew their consent to participate in the UK biobank study 
(section: Genotyping and imputation).
3.   Replication
Describe whether the experimental findings were 
reliably reproduced.
We used a meta-analytic approach, which inherently evaluates the combined 
evidence for significant association across samples. In addition, we used polygenic 
risk score profiling to determine whether our current results were predictive of the 
same outcome in three independent samples.
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
NA
5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
NA
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more 
complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
Standard statistical genetics software packages were used for the analyses 
described in the current manuscript (all are described in more detail in the Online 
Methods). Below we list the software used: 
Plink - Open-source software (Purcell et al., 2007; Chang et al., 2015) used to 
conduct genome-wide association analyses. 
MAGMA - In-house developed software (de Leeuw et al., 2015) for performing 
gene-based analyses. 
FUMA - In-house developed online platform for functional annotation of GWAS 
results (Watanabe et al., 2017) 
LD Score Regression - Used to compute SNP-based heritability and genetic 
correlations (Bulik-Sullivan et al., 2015) 
PRSice - Polygenic Risk Score analysis (Euesden et al., 2015) 
LDpred - Polygenic Risk Score analysis (Vilhjálmsson et al., 2015) 
GSMR - Generalized Summary-based Mendelian Randomization (Zhu, Z. et al. 2018)
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
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   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a for-profit company.
Summary statistics from our neuroticism meta-analysis, our depression meta-
analysis, and the GWA analyses for depressed affect and worry will be made 
available for download at https://ctg.cncr.nl/. Note that our freely available meta-
analytic sumstats concern results excluding the 23andMe sample. This is a non-
negotiable clause in the 23andMe data transfer agreement, intended to protect 
the privacy of the 23andMe research participants. 
23andMe participant data are shared according to community standards that have 
been developed to protect against breaches of privacy. Currently, these standards 
allow for the sharing of summary statistics for at most 10,000 SNPs. The full set of 
summary statistics can be made available to qualified investigators who enter into 
an agreement with 23andMe that protects participant confidentiality. Interested 
investigators should contact David Hinds (dhinds@23andme.com) for more 
information. 
Neuroticism summary statistics from the Genetics of Personality Consortium 
(GPC1) are freely available for download at: http://www.tweelingenregister.org/
GPC/ 
Depression summary statistics from the Psychiatric Genetics Consortium (PGC) are 
freely available for download at: https://www.nimhgenetics.org/available_data/
data_biosamples/pgc_public.php 
For further information, see Online Methods, section Data Availability.
9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
No antibodies were used.
10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. No eukaryotic cell lines were used.
b.  Describe the method of cell line authentication used. No eukaryotic cell lines were used.
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
No eukaryotic cell lines were used.
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide details on animals and/or animal-derived 
materials used in the study.
No animals were used in this study.
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
We utilized data collected previously by external sources. All individuals included in 
the study provided informed consent, and all original studies were approved by the 
concerned ethical committee (see Online Methods; section 'Samples')
